Fluticasone/salmeterol
Fluticasone propionate (top) and salmeterol (bottom) | |
| Combination of | |
|---|---|
| Fluticasone propionate | Glucocorticoid |
| Salmeterol | Long-acting beta-adrenoceptor agonist |
| Clinical data | |
| Trade names | Advair, Seretide, Cyplos, others |
| AHFS/Drugs.com | FDA Professional Drug Information |
| MedlinePlus | a699063 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| KEGG | |
| (verify) | |
Fluticasone/salmeterol, sold under the brand name Advair among others, is a fixed-dose combination medication containing fluticasone propionate, an inhaled corticosteroid; and salmeterol, a long-acting beta2‑adrenergic agonist. It is used in the management of asthma and chronic obstructive pulmonary disease (COPD). It is used by inhaling the medication into the lungs.
Common side effects include thrush, headache, and cough. Serious side effects may include worsening asthma, anaphylaxis, seizures, and heart problems. Safety in pregnancy and breastfeeding is unclear. Fluticasone, a corticosteroid, works by decreasing inflammation while salmeterol, a long-acting beta-adrenoceptor agonist (LABA), works by activating beta-2 adrenergic receptors.
The combination was approved for medical use in the United States in 2000. A generic version was approved in the United States in 2019. In 2022, it was the 59th most commonly prescribed medication in the United States, with more than 11 million prescriptions.